Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Antineoplastic Agents, Hormonal
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
Breast Neoplasms
/ diagnosis
Female
Follow-Up Studies
Humans
Lymph Nodes
/ pathology
Neoplasm Metastasis
Prognosis
Proportional Hazards Models
Receptor, ErbB-2
/ genetics
Receptors, Estrogen
/ genetics
Recurrence
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
received:
30
01
2019
revised:
09
04
2019
accepted:
02
05
2019
pubmed:
9
5
2019
medline:
6
8
2020
entrez:
9
5
2019
Statut:
ppublish
Résumé
Prognostic molecular assays may aid in treatment decisions for women with estrogen receptor (ER)-positive, HER2-negative breast cancer. The prognostic value of a 12-gene expression assay (EndoPredict) was reevaluated in the combined ABCSG-6/8 cohorts with longer clinical follow-up. EndoPredict (EP; molecular score, EPclin score) was evaluated in women with ER-positive, HER2-negative node-positive and node-negative breast cancer who received 5 years of endocrine therapy only (median follow-up, 9.6 years; Overall, 62.6% of patients had low-risk EPclin scores with significantly improved DRFR relative to high-risk patients (HR, 4.77; 95% CI, 3.37-6.67; This study demonstrates that EPclin can identify patients at low risk for early or late recurrence who may safely forgo adjuvant chemotherapy or extended endocrine therapy, respectively, regardless of nodal status.
Identifiants
pubmed: 31064782
pii: 1078-0432.CCR-19-0376
doi: 10.1158/1078-0432.CCR-19-0376
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3865-3872Informations de copyright
©2019 American Association for Cancer Research.